1300 Rancho Conejo Blvd.
About Capsida Biotherapeutics
Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders.
In the past, nearly all gene therapies have been aimed at treating rare disorders in infants – partially because of tremendous unmet need in those patients but mainly because of the limitations of naturally occurring AAV capsids. At Capsida, we’re not limited by the way things have always been done. We’ve developed a high throughput platform to biologically screen and identify proprietary engineered capsids to significantly improve target specificity and penetration in disease tissues and cells, allowing the use of gene therapy in both rare and common diseases across all ages.
Through intravenous (IV) delivery of a single, engineered capsid, Capsida’s technology can target single or multiple organs simultaneously while limiting exposure to non-targeted organs.
We harness the power of our diverse backgrounds and thoughts to deliver on our purpose. We have a sense of collective responsibility and unity. We approach every challenge with energy and excitement. We remain resilient in the face of adversity because we understand innovative science is not easy. We blend innovation with execution in the pursuit to improve patient lives. We’re not limited by the way things have always been done.
Seize the opportunity to be at the forefront of gene therapy. Capsida is a rapidly growing company based in the heart of the Greater Los Angeles biotech hub. We’re looking for passionate, dedicated colleagues to join us.
• Medical, dental, vision, prescription drug coverage
• Multiple plan options including PPO and HMO
• Employee and dependent coverage is 100% company funded (95% company funded for PPO option)
• Medical insurance waiver benefit if you have other coverage
• Competitive base salary
• Bonus program
• Equity participation
• Life and disability Insurance
• 401k plan
• Paid parental leave
• Competitive PTO, paid holidays and a winter shutdown
• Employee Resource Groups
• Employee Assistance Program
• On-site snacks
21 articles about Capsida Biotherapeutics
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx's Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. ("Capsida") and Kate Therapeutics ("KateTx") today announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs.
Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa
Capsida Biotherapeutics ("Capsida") today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the following upcoming investor and industry conferences.
Capsida Biotherapeutics Announces Publication in Nature Nanotechnology Identifying Novel Capsid With Significantly Increased Brain Transduction
Capsida Biotherapeutics ("Capsida") today announced research published in Nature Nanotechnology describing an adeno-associated virus (AAV) variant that can more effectively transduce the brain in non-human primates (NHPs) than AAV9.
Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy
Capsida Biotherapeutics ("Capsida") today announced it will present new preclinical data showing the potential for its engineered adeno-associated virus (AAV) therapeutics to treat genetic epilepsy caused by mutations in the syntaxin-binding protein 1 (STXBP1) gene.
Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting
Capsida Biotherapeutics ("Capsida") today announced it will present preliminary data on the company's next-generation engineered adeno-associated virus (AAV) capsids in non-human primates.
Capsida Biotherapeutics Inc. ("Capsida") today announced the appointment of Susan Catalano, Ph.D., as the company's Chief Scientific Officer (CSO).
With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need.
Capsida Biotherapeutics Inc. ("Capsida") today announced the appointment of Julie Hakim to the role of chief financial officer (CFO).
Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases
Capsida Biotherapeutics Inc. ("Capsida") today announced a multi-year strategic collaboration with Prevail Therapeutics ("Prevail"), a wholly owned subsidiary of Eli Lilly and Company ("Lilly"), to develop transformative genetic medicines for serious diseases.
Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
The American Society of Gene and Cell Therapy annual meeting continues to see companies showcasing promising therapeutics for multiple disease indications.
Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Capsida Biotherapeutics ("Capsida"), the only fully integrated gene therapy platform company that through intravenous (IV) delivery of a single, engineered capsid can target single or multiple organs simultaneously while limiting exposure to non-targeted organs, today announced an oral presentation and a poster presentation delivered at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
Capsida Biotherapeutics Inc. today announced the appointment of Rayne Waller to an expanded role as chief operating officer (COO).
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver
Capsida Biotherapeutics, Inc.,today announced research published in Nature Neuroscience that demonstrated the ability to engineer and select novel capsid variants, with improved enrichment in the brain and decreased liver targeting following intravenous (IV) administration in rodents and non-human primates.
Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO
Capsida Biotherapeutics Inc. today announced the appointment of Peter Anastasiou as the company's Chief Executive Officer (CEO) and the promotions of Capsida co-founders Nicholas Flytzanis, Ph.D., to Chief Scientific Officer (CSO) and Nick Goeden, Ph.D., to Chief Technology Officer (CTO).
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, today announced the opening of its state-of-the-art manufacturing facility in Thousand Oaks.